Edward Benz

Edward Benz, Jr. is a prominent Professor at Harvard Medical School and a leading figure in hematology and oncology. He serves as President and CEO of the Dana-Farber Cancer Institute, CEO of Dana-Farber/Partners CancerCare, and Director of the Dana-Farber/Harvard Cancer Center. His work bridges academic research, clinical leadership, and national policy in cancer care and blood disorders.

• Bachelor’s Degree – Princeton University
• MD – Harvard Medical School
• Internship & Residency – Brigham and Women’s Hospital
• Fellowships – National Institutes of Health, Boston Children’s Hospital, Yale University

Dr. Benz’s research focuses on the molecular pathology of red blood cell development, particularly the role of protein 4.1R in gene regulation, alternative splicing, and erythroid differentiation. His lab investigates how defects in this cytoskeletal protein contribute to inherited hemolytic anemias such as hereditary elliptocytosis and thalassemia. He has pioneered the study of tissue-specific and stage-specific splicing of the 4.1R gene, identifying key splicing factors and regulatory motifs. His work also extends to mitosis, cell junctions, and muscle biology, revealing broader roles for 4.1R beyond erythrocytes.

The 15 most recent publications reflect a dual trajectory: continued deep molecular investigation into protein 4.1R and erythropoiesis, alongside high-impact commentary on sickle cell disease, thalassemia, cancer care delivery, workforce challenges, and genetic therapies. His work combines basic science discovery with translational and policy-oriented perspectives, particularly in equity, access, and the future of academic medicine.

Notable scientific honors include:

• Former President of the American Society of Hematology (ASH)
• Former President of the American Society for Clinical Investigation (ASCI)
• Former President of the Association of American Cancer Institutes (AACI)
• Current President of the Association of Cancer Care Administrators (ACCA)
• Recipient of the George M. Kober Medal from the Association of American Physicians

Dr. Benz has played a critical role in mentoring future leaders in medicine and science through his leadership at Dana-Farber and Harvard, though specific advisees are not listed. He has secured major institutional grants as Principal Investigator of the Dana-Farber/Harvard Cancer Center. His influence extends to editorial roles, including founding the American Journal of Blood Research, and shaping national discourse on cancer policy, workforce development, and genetic medicine.

He leads or has been integral to major research units including the Dana-Farber Boston Children’s Cancer and Blood Disorders Center, the Hematology and Oncology Research program, and the Dana-Farber/Harvard Cancer Center. His lab continues to explore the multifunctional roles of protein 4.1R in cell biology and disease.